P/E ratio for Astec Lifesciences (ASTEC.NS)
P/E ratio as of April 2024 (TTM): -92.0
According to Astec Lifesciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -91.9794. At the end of 2022 the company had a P/E ratio of 46.6.
P/E ratio history for Astec Lifesciences from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 46.6 | 17.53% |
| 2021 | 39.7 | 13.5% |
| 2020 | 34.9 | 13.94% |
| 2019 | 30.7 | 15.2% |
| 2018 | 26.6 | -47.08% |
| 2017 | 50.3 | 12.12% |
| 2016 | 44.9 | -76.58% |
| 2015 | 192 | -22.01% |
| 2014 | 246 | 4046.36% |
| 2013 | 5.92 | -75.7% |
| 2012 | 24.4 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.